Italia markets open in 3 hours 37 minutes

CYTK May 2024 66.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,85000,0000 (0,00%)
In data: 10:14AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente2,8500
Aperto5,3000
Denaro0,0000
Domanda1,6500
Prezzo d'esercizio66,00
Scadenza2024-05-17
Min-Max giorno2,8500 - 5,3000
Contratto - Min-MaxN/D
Volume4
Open Interest13
  • GlobeNewswire

    Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions

    Topline Results from SEQUOIA-HCM Expected by End of YearSOUTH SAN FRANCISCO, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the baseline characteristics of patients randomized in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented at the HCM Society

  • GlobeNewswire

    Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023

    SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a virtual Investor and Analyst Day on Thursday, October 19, 2023 from 8:30 AM to 11:30 AM ET. The event, entitled New Horizons in Hypercontractility, will feature presentations from senior leaders about the Company’s cardiac myosin inhibition programs in hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), including n

  • GlobeNewswire

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 29, 2023 it granted stock options to purchase an aggregate of 5,700 shares of common stock to two new employees, whose employment commenced in September 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $29.46 per share, which is equal to the closing price of the Company’s common stock